Drugs / SI-F019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04851444 | Mar → Sep 2021 | — | Sichuan Baili Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-12-19 | Sichuan Biokin Pharmaceutical Co., Ltd. | Results 百利天恒首次公开发行股票并在科创板上市招股意向书 cninfo.com.cn ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-19 | Sichuan Biokin Pharmaceutical Co., Ltd. | 百利天恒首次公开发行股票并在科创板上市招股意向书 cninfo.com.cn ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SI-F019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04851444 ↗ |
| Modality | Protein / enzyme biologic | “SI-F019 recombinant human bivalent ACE2-Fc fusion protein injection” NCT04851444 ↗ |
| Route | Intravenous | “SI-F019 administered intravenously (IV).” NCT04851444 ↗ |